I kind of had a feeling the Trump news was going to involve lenzilumab, not Regeneron's cocktail which has just enrolling for Phase1/2/3 combo. Gilead was probably desperate to improve the performance of Remdesivir. It is disappointing because leronlimab is the better drug for Covid, but I don't think it is entirely negative. Now MABs are really in the spotlight. Just pray we have awesome data.